A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis

Completed · Phase 3 · Has a placebo group

Conditions studied: Ankylosing Spondylitis

In brief

The purpose of the study is to demonstrate the efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active ankylosing spondylitis (AS).

Key facts

Study ID

NCT03928743

Run by

UCB Biopharma SRL

People needed

332

Starts

2019-04-25

Expected to finish

2022-08-08

Last updated by the study team

2025-12-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female patients at least 18 years of age
• Subject has ankylosing spondylitis (AS) as per the Modified New York (mNY) criteria with documented radiologic evidence, and at least 3 months of symptoms with age at symptom onset less than 45 years
• Subjects has moderate-to-severe active disease defined by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) >=4 AND spinal pain >=4 on a 0 to 10 Numeric Rating Scale
• Subjects had to have either failed to respond to 2 different nonsteroidal anti-inflammatory drugs (NSAIDs) given at the maximum tolerated dose for a total of 4 weeks or have a history of intolerance to or a contraindication to NSAID therapy
• Patients who have taken a tumor necrosis factor alpha (TNFα) inhibitor must have experienced an inadequate response or intolerance to treatment given at an approved dose for at least 12 weeks
• Patients currently taking NSAIDs, cyclooxygenase 2 (COX-2) inhibitors, analgesics, corticosteroids, methotrexate (MTX), leflunomide (LEF), sulfasalazine (SSZ), hydroxychloroquine (HCQ) AND/OR apremilast can be allowed if they fulfill specific requirements prior to study entry

You may not qualify if…

• Total ankylosis of the spine
• Treatment with more than 1 TNFα inhibitor and/or more than 2 additional non-TNFα biological response modifiers, or any interleukin (IL)-17 biological response modifier at any time are excluded
• Active infection or history of recent serious infections
• Viral hepatitis B or C or human immunodeficiency virus (HIV) infection
• Any live (includes attenuated) vaccination within the 8 weeks prior to entering the study or TB (Bacillus Calmette-Guerin) vaccination within 1 year prior entering the study
• Known tuberculosis (TB) infection, at high risk of acquiring TB infection, or current or history of nontuberculous mycobacterium (NTMB) infection
• Subject has any active malignancy or history of malignancy within 5 years prior to the Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma or in situ cervical cancer
• Diagnosis of inflammatory conditions other than AxSpA, eg, rheumatoid arthritis. Patients with a diagnosis of Crohn's disease, ulcerative colitis, or other inflammatory bowel disease (IBD) are allowed as long as they have no active symptomatic disease when entering the study.
• Presence of active suicidal ideation, or moderately severe major depression or severe major depression
• Female patients who are breastfeeding, pregnant, or planning to become pregnant during the study
• Subject has a history of chronic alcohol or drug abuse within 6 months prior to Screening

Where it is running

• As0011 50052 — Phoenix, Arizona, United States
• As0011 50058 — Phoenix, Arizona, United States
• As0011 50062 — Sun City, Arizona, United States
• As0011 50060 — Upland, California, United States
• As0011 50056 — Sarasota, Florida, United States
• As0011 50015 — Hagerstown, Maryland, United States
• As0011 50016 — St Louis, Missouri, United States
• As0011 50054 — Oklahoma City, Oklahoma, United States
• As0011 50020 — Duncansville, Pennsylvania, United States
• As0011 50001 — Jackson, Tennessee, United States
• As0011 50012 — Memphis, Tennessee, United States
• As0011 50057 — Dallas, Texas, United States
• As0011 50036 — Mesquite, Texas, United States
• As0011 40004 — Brussels, Belgium
• As0011 40003 — Genk, Belgium
• As0011 40001 — Ghent, Belgium
• As0011 40006 — Plovdiv, Bulgaria
• As0011 40007 — Plovdiv, Bulgaria
• As0011 40005 — Sofia, Bulgaria
• As0011 40008 — Sofia, Bulgaria
• As0011 20040 — Beijing, China
• As0011 20021 — Chengdu, China
• As0011 20019 — Guangzhou, China
• As0011 20034 — Hefei, China
• As0011 50131 — Mesa, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.